AbbVie Inc. or TG Therapeutics, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: AbbVie Inc. or TG Therapeutics, Inc.?

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, AbbVie Inc. and TG Therapeutics, Inc. have shown contrasting approaches to handling these costs.

A Decade of Financial Insights

From 2014 to 2023, AbbVie Inc. consistently reported higher SG&A expenses, peaking at approximately $12.9 billion in 2023. This reflects a strategic investment in marketing and administrative capabilities, essential for a company of its scale. In contrast, TG Therapeutics, Inc. maintained a leaner SG&A structure, with expenses reaching around $122 million in 2023. This represents a modest increase from 2014, showcasing their focus on cost efficiency.

Strategic Implications

While AbbVie's higher expenses might indicate aggressive market expansion, TG Therapeutics' approach suggests a focus on sustainable growth. Investors and stakeholders should consider these strategies when evaluating long-term potential.